Inivata_CMYK_Logo.jpg
Inivata to be Acquired by NeoGenomics
May 05, 2021 07:00 ET | Inivata
Inivata to be Acquired by NeoGenomics Exercise of purchase option to acquire remaining Inivata equity interest for $390m Inivata to become a liquid biopsy focused division of NeoGenomics Research...
Inivata_CMYK_Logo.jpg
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer
April 28, 2021 07:00 ET | Inivata
Inivata and Agendia Sign Agreement for Commercialization of RaDaR® MRD Liquid Biopsy Assay in Breast Cancer Agendia granted co-exclusive distribution rights for RaDaR in North America and Europe ...
Inivata_CMYK_Logo.jpg
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021
April 10, 2021 08:30 ET | Inivata
Inivata Presents New Data in Support of its Liquid Biopsy Technologies at AACR Virtual Annual Meeting 2021 Inivata’s RaDaR® MRD assay performed with exceptionally high sensitivity and...
Inivata_CMYK_Logo.jpg
Inivata to Present New Data in Support of its RaDaR™ MRD and InVisionFirst®-Lung tests at AACR Virtual Annual Meeting 2021
March 17, 2021 08:00 ET | Inivata
Inivata to Present New Data in Support of its RaDaR™ MRD and InVisionFirst®-Lung tests at AACR Virtual Annual Meeting 2021 Research Triangle Park, NC, USA and Cambridge, UK, 17 March 2021 --...
Inivata_CMYK_Logo.jpg
FDA Grants Breakthrough Device Designation for Inivata’s RaDaR™ Assay
March 09, 2021 07:00 ET | Inivata
FDA Grants Breakthrough Device Designation for Inivata’s RaDaR™ Assay Designation will help accelerate the regulatory path of RaDaR for use in detection of MRD in early-stage cancer patients ...
Inivata_CMYK_Logo.jpg
Inivata Raises $35 million in Second Close of Series C Financing
February 04, 2021 07:00 ET | Inivata
Inivata Raises $35 million in Second Close of Series C Financing Funds will accelerate clinical development of RaDaR™ minimal residual disease assay and commercialization of InVisionFirst®-Lung ...
Inivata_CMYK_Logo.jpg
First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
January 20, 2021 07:00 ET | Inivata
                First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study Inivata’s InVisionFirst®-Lung is being used for ctDNA testing and monitoring of patients...
Inivata_CMYK_Logo.jpg
Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer
December 18, 2020 07:00 ET | Inivata
Inivata’s Liquid Biopsy Technology Included in Unique £10m Research Collaboration for Early Detection of Lung Cancer Research Collaboration to be led by the University of Southampton and along with...
Inivata_CMYK_Logo.jpg
Inivata Appoints Dr. Alan Schafer as Chief Technology Officer
November 16, 2020 07:00 ET | Inivata
Inivata Appoints Dr. Alan Schafer as Chief Technology Officer Research Triangle Park, NC, USA and Cambridge, UK, 16 November 2020 – Inivata, a leader in liquid biopsy, today announces the...
Inivata_CMYK_Logo.jpg
Inivata Announces Collaboration with Maverick Therapeutics for use of RaDaR™ Assay
October 29, 2020 07:00 ET | Inivata
Inivata Announces Collaboration with Maverick Therapeutics for use of RaDaR™ Assay RaDaR ctDNA liquid biopsy test to be used to monitor patient response in Phase 1/2 study of MVC-101 in multiple...